source
- STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and moreIntellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with hereditary angioedemaSTAT · 3mo ago↗ source
- Intellia CRISPR drug succeeds in late-stage study against rare swelling disorderThe findings position Intellia to bring to market the first “in vivo” gene editing medicine, though the therapy’s commercial potential remains the source of intense investor debate.BioPharma Dive · 3mo ago↗ source
- What’s the true risk for eating disorders with GLP-1s?The state of Covid-19 in 2026, a hat to treat depression, and other health news from Morning RoundsSTAT · 3mo ago